EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment

Willians Tambo, Keren Powell, Steven Wadolowski, Prashin Unadkat, Eric H Chang, Christopher LeDoux, Daniel Sciubba, Ping Wang, Patricio Huerta, Chunyan Li

Alzheimer's & Dementia · 2025-11 · 21 (11)

DOI: 10.1002/alz.70925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.11.2025. Verfasst von Willians Tambo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Brain Research Laboratory, The Feinstein Institutes for Medical Research, Manhasset, New York, USA. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Neuropeptides, Microvessels, Dementia, Vascular. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Army Medical Research Acquisition Activity (USAMRAA), US Army Medical Research and Materiel Command (USAMRMC), Zoll Foundation Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Neuropeptide dysregulation and microvascular injury are involved in pathogenesis of vascular cognitive impairment (VCI); however, the underlying etiology of this pathological axis remains unclear. METHODS We investigated pathological mediators across varying severities of VCI in a rat model of chronic cerebral hypoperfusion (CCH). Proteomic analysis guided the evaluation of neuropeptide and non‐neuropeptide markers associated with vascular and non‐vascular dysfunction, which were correlated with cognitive function to determine their role in VCI. RESULTS Proteomic analysis revealed vasomotor dysfunction as the primary pathological pathway in VCI. Microvascular vasoconstriction was the earliest and most persistent event, initiating a cascade of both microvascular and non‐vascular dysfunction. Dysregulation of vasoactive neuropeptides was identified as the key driver of this process. Calcitonin gene‐related peptide (CGRP) supplementation effectively prevented vasoconstriction, and improved cognitive function in CCH. DISCUSSION This study suggests dysregulation of vasoactive neuropeptides plays a central role in CCH pathomechanism, with microvascular vasoconstriction acting as the primary mediator. Highlights Neuropeptides are the primary drivers of dominant pathomechanisms underlying chronic cerebral hypoperfusion (CCH). Early vasoactive neuropeptide dysregulation is a key driver of cognitive decline. Microvascular dysfunction precedes classical non‐vascular pathologies in CCH. Capillary constriction precedes and drives amyloid accumulation in CCH. CGRP mitigates microvascular constriction, enhancing cognitive function in VCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionNeuropeptidesMicrovesselsDementia, VascularAnimalsMaleRatsCalcitonin Gene-Related PeptideDisease Models, AnimalRats, Sprague-DawleyVasoconstrictionProteomicsCerebrovascular Circulation

Stichwörter der Autor:innen

CGRPmicrovascularneuropeptidesproteomicsvascular cognitive impairmentvasoconstriction

Substanzen

NeuropeptidesCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Translational Brain Research Laboratory, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Elmezzi Graduate School of Molecular Medicine at Northwell Health, Manhasset, New York, USA.
  • Institute of Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Department of Neurosurgery, North Shore University Hospital at Northwell Health, Manhasset, New York, USA.
  • Department of Biology, Hofstra University, Hempstead, New York, USA.
  • Center for Immunology and Inflammation, Feinstein Institutes for Medical Research, Manhasset, New York, USA.

Förderung

  • United States Army Medical Research Acquisition Activity (USAMRAA)
  • US Army Medical Research and Materiel Command (USAMRMC)
  • Zoll Foundation Award
  • The Feinstein Institutes for Medical Research
  • Advancing Women in Science and Medicine at the Feinstein Institutes for Medical Research

Zitieren

APA

Tambo, W., Powell, K., Wadolowski, S., Unadkat, P., Chang, E. H., LeDoux, C., Sciubba, D., Wang, P., Huerta, P., & Li, C. (2025). Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment. Alzheimer's & Dementia, 21(11). https://doi.org/10.1002/alz.70925

Vancouver

Tambo W, Powell K, Wadolowski S, Unadkat P, Chang EH, LeDoux C, et al. Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment. Alzheimer's & Dementia. 2025;21(11). doi:10.1002/alz.70925

BibTeX
@article{Tambo2025,
  author = {Tambo, Willians and Powell, Keren and Wadolowski, Steven and Unadkat, Prashin and Chang, Eric H and LeDoux, Christopher and Sciubba, Daniel and Wang, Ping and Huerta, Patricio and Li, Chunyan},
  title = {Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {11},
  doi = {10.1002/alz.70925}
}
Kostenlos starten →